ArriVent Biopharma Inc. has outlined updates on its global oncology pipeline, highlighting its lead program, firmonertinib, which has received Breakthrough Therapy Designation for first-line treatment of EGFR Exon 20 insertion mutant non-small cell lung cancer (NSCLC). The company expects topline results from a registrational study in early 2026 and is expanding firmonertinib into a pivotal trial for first-line EGFR PACC mutant NSCLC, supported by positive clinical data. ArriVent is also advancing its next-generation antibody-drug conjugate $(ADC)$ portfolio, with ARR-217 currently in Phase 1 trials for gastrointestinal tumors and additional ADC programs expected to enter clinical development in 2026. The pipeline includes multiple programs in various stages targeting solid tumors and NSCLC, with global development efforts outside China. You can access the full presentation through the link below.